GlobeNewswire
-
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
01/06/2026 -
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
01/06/2026 -
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
01/06/2026 -
Caring Brands Inc. and SanPellegrino Cosmetics Private Limited Announce Expanded Multi-Territory Licensing Agreement for Photocil and Hair Enzyme Booster
01/06/2026 -
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
01/06/2026 -
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
01/06/2026 -
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis
01/06/2026 -
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
01/06/2026 -
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/06/2026 -
Spectral AI Announces Voting Results of Annual Meeting of Stockholders
01/06/2026 -
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
01/06/2026 -
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
01/06/2026 -
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
01/06/2026 -
Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing
01/06/2026 -
Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases
01/06/2026 -
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
01/06/2026 -
ITM Announces Phase 3 COMPETE Data Supporting Single-Timepoint Dosimetry for n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at SNMMI 2026
01/06/2026 -
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
01/06/2026 -
Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026
01/06/2026
Pages